Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 101

1.

Quality Monitoring of a FIT-Based Colorectal Cancer Screening Program.

Toes-Zoutendijk E, Bonfrer JMG, Ramakers C, Thelen M, Spaander MCW, Dekker E, van der Meulen MP, Buskermolen M, van Vuuren AJ, Kuipers EJ, van Kemenade FJ, van Velthuysen MF, Thomeer MGJ, van Veldhuizen H, van Ballegooijen M, de Koning HJ, van Leerdam ME, Lansdorp-Vogelaar I.

Clin Chem. 2019 Mar;65(3):419-426. doi: 10.1373/clinchem.2018.294041. Epub 2019 Jan 16.

PMID:
30651228
2.

Real-Time Monitoring of Results During First Year of Dutch Colorectal Cancer Screening Program and Optimization by Altering Fecal Immunochemical Test Cut-Off Levels.

Toes-Zoutendijk E, van Leerdam ME, Dekker E, van Hees F, Penning C, Nagtegaal I, van der Meulen MP, van Vuuren AJ, Kuipers EJ, Bonfrer JMG, Biermann K, Thomeer MGJ, van Veldhuizen H, Kroep S, van Ballegooijen M, Meijer GA, de Koning HJ, Spaander MCW, Lansdorp-Vogelaar I; Dutch National Colorectal Cancer Screening Working Group.

Gastroenterology. 2017 Mar;152(4):767-775.e2. doi: 10.1053/j.gastro.2016.11.022. Epub 2016 Nov 24.

PMID:
27890769
3.

Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor Markers.

Sölétormos G, Duffy MJ, Othman Abu Hassan S, Verheijen RH, Tholander B, Bast RC Jr, Gaarenstroom KN, Sturgeon CM, Bonfrer JM, Petersen PH, Troonen H, CarloTorre G, Kanty Kulpa J, Tuxen MK, Molina R.

Int J Gynecol Cancer. 2016 Jan;26(1):43-51. doi: 10.1097/IGC.0000000000000586.

4.

[Faecal occult blood test for colorectal cancer screening: high quality for a good price].

van Veldhuizen H, Bonfrer JM, Kuipers EJ.

Ned Tijdschr Geneeskd. 2013;157(16):A6330. Dutch.

PMID:
23594877
5.

Design of tumor biomarker-monitoring trials: a proposal by the European Group on Tumor Markers.

Sölétormos G, Duffy MJ, Hayes DF, Sturgeon CM, Barak V, Bossuyt PM, Diamandis EP, Gion M, Hyltoft-Petersen P, Lamerz RM, Nielsen DL, Sibley P, Tholander B, Tuxen MK, Bonfrer JM.

Clin Chem. 2013 Jan;59(1):52-9. doi: 10.1373/clinchem.2011.180778. Epub 2012 Oct 3.

6.

Choice of tumour markers in patients with neuroendocrine tumours is dependent on the histological grade. A marker study of Chromogranin A, Neuron specific enolase, Progastrin-releasing peptide and cytokeratin fragments.

Korse CM, Taal BG, Vincent A, van Velthuysen ML, Baas P, Buning-Kager JC, Linders TC, Bonfrer JM.

Eur J Cancer. 2012 Mar;48(5):662-71. doi: 10.1016/j.ejca.2011.08.012. Epub 2011 Sep 22.

PMID:
21945100
7.

An elevated progastrin-releasing peptide level in patients with well-differentiated neuroendocrine tumours indicates a primary tumour in the lung and predicts a shorter survival.

Korse CM, Taal BG, Bonfrer JM, Vincent A, van Velthuysen ML, Baas P.

Ann Oncol. 2011 Dec;22(12):2625-30. doi: 10.1093/annonc/mdr007. Epub 2011 Mar 17.

PMID:
21415235
8.

Increase of angiogenic growth factors after hepatic artery embolization in patients with neuroendocrine tumours.

Korse CM, Bonfrer JM, Prevoo W, Baas P, Taal BG.

Tumour Biol. 2011 Aug;32(4):647-52. doi: 10.1007/s13277-011-0164-7. Epub 2011 Mar 5.

PMID:
21373992
9.

Utility of FDG PET/CT and brain MRI in melanoma patients with increased serum S-100B level during follow-up.

Aukema TS, Olmos RA, Korse CM, Kroon BB, Wouters MW, Vogel WV, Bonfrer JM, Nieweg OE.

Ann Surg Oncol. 2010 Jun;17(6):1657-61. doi: 10.1245/s10434-010-0963-x. Epub 2010 Feb 12.

PMID:
20151211
10.

Soluble epidermal growth factor receptor (sEGFR) and carcinoembryonic antigen (CEA) concentration in patients with non-small cell lung cancer: correlation with survival after erlotinib and gefitinib treatment.

Kappers I, Vollebergh MA, van Tinteren H, Korse CM, Nieuwenhuis LL, Bonfrer JM, Klomp HM, van Zandwijk N, van den Heuvel MM.

Ecancermedicalscience. 2010;4:178. doi: 10.3332/ecancer.2010.178. Epub 2010 Nov 3.

11.

[Application of tumour markers in clinical practice].

Keuren JF, Thomas CM, Bonfrèr JM, Sweep CG, Boonstra JG.

Ned Tijdschr Geneeskd. 2009;153:A617. Review. Dutch.

PMID:
19857306
12.

Chromogranin-A and N-terminal pro-brain natriuretic peptide: an excellent pair of biomarkers for diagnostics in patients with neuroendocrine tumor.

Korse CM, Taal BG, de Groot CA, Bakker RH, Bonfrer JM.

J Clin Oncol. 2009 Sep 10;27(26):4293-9. doi: 10.1200/JCO.2008.18.7047. Epub 2009 Aug 10.

PMID:
19667278
13.

Serum S100B in elderly patients with and without delirium.

van Munster BC, Korevaar JC, Korse CM, Bonfrer JM, Zwinderman AH, de Rooij SE.

Int J Geriatr Psychiatry. 2010 Mar;25(3):234-9. doi: 10.1002/gps.2326.

PMID:
19575407
14.

Serum protein profiling for diagnosis of breast cancer using SELDI-TOF MS.

Gast MC, Van Gils CH, Wessels LF, Harris N, Bonfrer JM, Rutgers EJ, Schellens JH, Beijnen JH.

Oncol Rep. 2009 Jul;22(1):205-13.

PMID:
19513525
15.

Markers of cerebral damage during delirium in elderly patients with hip fracture.

van Munster BC, Korse CM, de Rooij SE, Bonfrer JM, Zwinderman AH, Korevaar JC.

BMC Neurol. 2009 May 27;9:21. doi: 10.1186/1471-2377-9-21.

16.

Influence of sample storage duration on serum protein profiles assessed by surface-enhanced laser desorption/ionisation time-of-flight mass spectrometry (SELDI-TOF MS).

Gast MC, van Gils CH, Wessels LF, Harris N, Bonfrer JM, Rutgers EJ, Schellens JH, Beijnen JH.

Clin Chem Lab Med. 2009;47(6):694-705. doi: 10.1515/CCLM.2009.151.

PMID:
19416081
17.

Estradiol and testosterone levels are lower after oophorectomy than after natural menopause.

Korse CM, Bonfrer JM, van Beurden M, Verheijen RH, Rookus MA.

Tumour Biol. 2009;30(1):37-42. doi: 10.1159/000199449. Epub 2009 Feb 5.

PMID:
19194113
18.

No effect of red clover-derived isoflavone intervention on the insulin-like growth factor system in women at increased risk of colorectal cancer.

Vrieling A, Rookus MA, Kampman E, Bonfrer JM, Bosma A, Cats A, van Doorn J, Korse CM, Witteman BJ, van Leeuwen FE, van't Veer LJ, Voskuil DW.

Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2585-93. doi: 10.1158/1055-9965.EPI-08-0329.

19.

Chromogranin A as an alternative to 5-hydroxyindoleacetic acid in the evaluation of symptoms during treatment of patients with neuroendocrine Tumors.

Korse CM, Bonfrer JM, Aaronson NK, Hart AA, Taal BG.

Neuroendocrinology. 2009;89(3):296-301. doi: 10.1159/000162876. Epub 2008 Oct 7.

PMID:
18840995
20.

Value of serum S-100B for prediction of distant relapse and survival in stage III B/C melanoma.

Smit LH, Nieweg OE, Mooi WJ, Bonfrer JM, Haanen JB, Kroon BB, De Gast GC.

Anticancer Res. 2008 Jul-Aug;28(4C):2297-302.

21.

Effects of lycopene on the insulin-like growth factor (IGF) system in premenopausal breast cancer survivors and women at high familial breast cancer risk.

Voskuil DW, Vrieling A, Korse CM, Beijnen JH, Bonfrer JM, van Doorn J, Kaas R, Oldenburg HS, Russell NS, Rutgers EJ, Verhoef S, van Leeuwen FE, van't Veer LJ, Rookus MA.

Nutr Cancer. 2008;60(3):342-53. doi: 10.1080/01635580701861777.

PMID:
18444168
22.

Re: C-reactive protein and risk of breast cancer.

Zeleniuch-Jacquotte A, Gu Y, Bruning PF, Bonfrer JM, Koenig KL, Arslan AA, Toniolo P, Shore RE.

J Natl Cancer Inst. 2008 Mar 19;100(6):443-4; author reply 444-5. doi: 10.1093/jnci/djn016. Epub 2008 Mar 11. No abstract available.

PMID:
18334713
23.

Lycopene supplementation elevates circulating insulin-like growth factor binding protein-1 and -2 concentrations in persons at greater risk of colorectal cancer.

Vrieling A, Voskuil DW, Bonfrer JM, Korse CM, van Doorn J, Cats A, Depla AC, Timmer R, Witteman BJ, van Leeuwen FE, Van't Veer LJ, Rookus MA, Kampman E.

Am J Clin Nutr. 2007 Nov;86(5):1456-62.

PMID:
17991659
24.

Non-invasive diagnosis of pleural malignancies: the role of tumour markers.

van den Heuvel MM, Korse CM, Bonfrer JM, Baas P.

Lung Cancer. 2008 Mar;59(3):350-4. Epub 2007 Oct 22.

PMID:
17933420
25.

Human papillomavirus-16 is the predominant type etiologically involved in penile squamous cell carcinoma.

Heideman DA, Waterboer T, Pawlita M, Delis-van Diemen P, Nindl I, Leijte JA, Bonfrer JM, Horenblas S, Meijer CJ, Snijders PJ.

J Clin Oncol. 2007 Oct 10;25(29):4550-6.

PMID:
17925550
26.

Validation of SELDI-TOF MS serum protein profiles for renal cell carcinoma in new populations.

Engwegen JY, Mehra N, Haanen JB, Bonfrer JM, Schellens JH, Voest EE, Beijnen JH.

Lab Invest. 2007 Feb;87(2):161-72.

27.

S-100B protein and melanoma inhibitory activity protein in uveal melanoma screening. A comparison with liver function tests.

Missotten GS, Korse CM, van Dehn C, Linders TC, Keunen JE, Jager MJ, Bonfrer JM.

Tumour Biol. 2007;28(2):63-9. Epub 2007 Jan 29.

PMID:
17264538
28.

SELDI-TOF MS serum protein profiles in breast cancer: assessment of robustness and validity.

Gast MC, Bonfrer JM, van Dulken EJ, de Kock L, Rutgers EJ, Schellens JH, Beijnen JH.

Cancer Biomark. 2006;2(6):235-48.

PMID:
17264395
29.

Isolated isoflavones do not affect the circulating insulin-like growth factor system in men at increased colorectal cancer risk.

Vrieling A, Rookus MA, Kampman E, Bonfrer JM, Korse CM, van Doorn J, Lampe JW, Cats A, Witteman BJ, van Leeuwen FE, van't Veer LJ, Voskuil DW.

J Nutr. 2007 Feb;137(2):379-83.

PMID:
17237315
30.

Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy.

Peeters ST, Heemsbergen WD, Koper PC, van Putten WL, Slot A, Dielwart MF, Bonfrer JM, Incrocci L, Lebesque JV.

J Clin Oncol. 2006 May 1;24(13):1990-6.

PMID:
16648499
31.

Identification of serum proteins discriminating colorectal cancer patients and healthy controls using surface-enhanced laser desorption ionisation-time of flight mass spectrometry.

Engwegen JY, Helgason HH, Cats A, Harris N, Bonfrer JM, Schellens JH, Beijnen JH.

World J Gastroenterol. 2006 Mar 14;12(10):1536-44.

32.

Immunophenotypic markers to differentiate between benign and malignant melanocytic lesions.

Keijser S, Missotten GS, Bonfrer JM, de Wolff-Rouendaal D, Jager MJ, de Keizer RJ.

Br J Ophthalmol. 2006 Feb;90(2):213-7.

33.

CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use.

Duffy MJ, Bonfrer JM, Kulpa J, Rustin GJ, Soletormos G, Torre GC, Tuxen MK, Zwirner M.

Int J Gynecol Cancer. 2005 Sep-Oct;15(5):679-91.

34.

MALDI-TOF mass spectrometry analysis of cerebrospinal fluid tryptic peptide profiles to diagnose leptomeningeal metastases in patients with breast cancer.

Dekker LJ, Boogerd W, Stockhammer G, Dalebout JC, Siccama I, Zheng P, Bonfrer JM, Verschuuren JJ, Jenster G, Verbeek MM, Luider TM, Smitt PA.

Mol Cell Proteomics. 2005 Sep;4(9):1341-9. Epub 2005 Jun 21.

35.

Significance of serum S-100B in melanoma patients before and after sentinel node biopsy.

Smit LH, Nieweg OE, Korse CM, Bonfrer JM, Kroon BB.

J Surg Oncol. 2005 May 1;90(2):66-9; discussion 69-70.

PMID:
15844182
36.

Comparison of four different assays for determination of serum S-100B.

Smit LH, Korse CM, Bonfrer JM.

Int J Biol Markers. 2005 Jan-Mar;20(1):34-42.

PMID:
15832771
37.

Normal values of serum S-100B predict prolonged survival for stage IV melanoma patients.

Smit LH, Korse CM, Hart AA, Bonfrer JM, Haanen JB, Kerst JM, Nieweg OE, de Gast GC.

Eur J Cancer. 2005 Feb;41(3):386-92.

PMID:
15691637
38.

Daily cyclic changes in the urinary excretion of 5-hydroxyindoleacetic acid in patients with carcinoid tumors.

Zuetenhorst JM, Korse CM, Bonfrer JM, Peter E, Lamers CB, Taal BG.

Clin Chem. 2004 Sep;50(9):1634-9. Epub 2004 Jul 9.

39.

Role of natriuretic peptides in the diagnosis and treatment of patients with carcinoid heart disease.

Zuetenhorst JM, Korse CM, Bonfrer JM, Bakker RH, Taal BG.

Br J Cancer. 2004 Jun 1;90(11):2073-9.

40.

Proteomics in uveal melanoma.

Missotten GS, Beijnen JH, Keunen JE, Bonfrer JM.

Melanoma Res. 2003 Dec;13(6):627-9.

PMID:
14646627
41.

Prognostic value of S-100-beta serum concentration in patients with uveal melanoma.

Missotten GS, Tang NE, Korse CM, Hurks HM, de Wolff-Rouendaal D, Keunen JE, Jager MJ, Bonfrer JM.

Arch Ophthalmol. 2003 Aug;121(8):1117-9.

PMID:
12912688
42.

Serum soluble CD27, but not thymidine kinase, is an independent prognostic factor for outcome in indolent non-Hodgkin's lymphoma.

Kok M, Bonfrer JM, Korse CM, de Jong D, Kersten MJ.

Tumour Biol. 2003 Jan-Feb;24(1):53-60.

PMID:
12743427
43.

Reactivity to human papillomavirus type 16 L1 virus-like particles in sera from patients with genital cancer and patients with carcinomas at five different extragenital sites.

Van Doornum GJ, Korse CM, Buning-Kager JC, Bonfrer JM, Horenblas S, Taal BG, Dillner J.

Br J Cancer. 2003 Apr 7;88(7):1095-100.

45.

Clinical evaluation of the Elecsys CA 15-3 test in breast cancer patients.

Stieber P, Molina R, Chan DW, Fritsche HA, Beyrau R, Bonfrer JM, Filella X, Gornet TG, Hoff T, Jäger W, van Kamp GJ, Nagel D, Peisker K, Sokoll LJ, Troalen F, Untch M, Domke I.

Clin Lab. 2003;49(1-2):15-24.

PMID:
12593471
46.

Serum S100B is suitable for prediction and monitoring of response to chemoimmunotherapy in metastatic malignant melanoma.

Hamberg AP, Korse CM, Bonfrer JM, de Gast GC.

Melanoma Res. 2003 Feb;13(1):45-9.

PMID:
12569284
48.

Plasma lysophosphatidic acid concentration and ovarian cancer.

Baker DL, Morrison P, Miller B, Riely CA, Tolley B, Westermann AM, Bonfrer JM, Bais E, Moolenaar WH, Tigyi G.

JAMA. 2002 Jun 19;287(23):3081-2. No abstract available.

PMID:
12069669
49.

Evaluation of the analytical and clinical performance of the Elecsys CA 15-3 immunoassay.

Stieber P, Molina R, Chan DW, Fritsche HA, Beyrau R, Bonfrer JM, Filella X, Gornet TG, Hoff T, Jäger W, van Kamp GJ, Nagel D, Peisker K, Sokoll LJ, Troalen F, Untch M, Domke I.

Clin Chem. 2001 Dec;47(12):2162-4. No abstract available.

50.

Monitoring malignant melanoma with the S-100B tumour marker.

Bonfrer JM, Korse CM.

Recent Results Cancer Res. 2001;158:149-57.

PMID:
11092042

Supplemental Content

Loading ...
Support Center